Diabetes drug target genes show no clear Parkinson’s link in humans
A genetic analysis of 42,083 Parkinson’s cases and 457,090 controls found no significant link between selected diabetes drug targets and disease risk.
Our read
Populations- Studied:
- Mendelian randomization in people with Parkinson's disease and PD-free controls
- What changed:
- Parkinson's disease risk and age at onset showed no clear association with genetic variation in diabetes drug targets
- The catch:
- DPP-4 genetic proxies failed the diabetes-risk validation check, weakening results for this drug class
- Stake:
- An author works for Novo Nordisk.
Editor of record: Boris Djordjevic · AgingResearch.News
Genetic data from 42,083 people with Parkinson’s disease and 457,090 people without it formed the basis of a Mendelian randomization analysis of diabetes drug targets. This method used inherited DNA differences as stand-ins for drug effects, rather than testing medicines in people. The researchers selected differences in or near genes for proteins that diabetes drugs act on, using blood sugar measures and gene activity data.
The analysis found no statistically significant links between these genetic stand-ins and Parkinson’s risk across two research consortia or in their combined results. An analysis of 37,103 people with Parkinson’s also found no significant links to age at onset. The findings did not support a causal role for genetic variation in these drug targets in Parkinson’s risk or onset age.
Why it matters
Parkinson’s, an age-related disease, is a potential target for prevention efforts. The analysis examined the biological rationale for repurposing existing diabetes medicines to prevent it or delay its onset.
Caveats
Genetic stand-ins do not measure the effects of taking medicines, and not every drug class could be reliably assessed. Statistical uncertainty varied widely across drug classes, and the analysis used European-population data.
From the paper
- Participants
For our meta-analyses of these two GWASes, our sample included 42 083 cases/457 090 controls for risk and 37 103 PD cases for AAO, thus resulting in the best-powered study so far.
Quoted word for word from the full text on PubMed Central.
The paper
Karolinska Institutet
NPJ Parkinson's Disease, May 28, 2026, Open access
Comments
Be the first to comment.